Gastric Cancer Stage IV Clinical Trial
Official title:
Phase I/II Study of the Combination of Irinotecan and POF (Paclitaxel Plus Oxaliplatin Plus 5-fluorouracil Plus Leucovorin) and Tislelizumab
The purpose of the phase I/II study is to establish the safety of Combination of Irinotecan and paclitaxel with 5-FU, leucovorin, oxaliplatin and Tislelizumab.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04592211 -
Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05301465 -
Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.
|
||
| Active, not recruiting |
NCT06034964 -
Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC
|
||
| Recruiting |
NCT05204173 -
Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis
|
Phase 2 | |
| Active, not recruiting |
NCT04267549 -
Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT06342427 -
Stomach Cancer Exosome-based Detection
|
||
| Recruiting |
NCT04563975 -
Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer
|
Phase 2 | |
| Terminated |
NCT04168931 -
Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC
|
Phase 2 | |
| Recruiting |
NCT03701373 -
Maintenance Treatment With S-1 in Gastric Cancer Patients
|
Phase 2 | |
| Completed |
NCT03618758 -
Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6
|
Phase 1/Phase 2 | |
| Completed |
NCT03755440 -
PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.
|
Phase 2 | |
| Completed |
NCT03159585 -
To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors
|
Phase 1 |